The combined treatment of 1,25-dihydroxyvitamin D3 and a non-steroid anti-inflammatory drug is highly effective in suppressing prostate cancer cell line (LNCaP) growth.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Anticancer Research

• Publication date

  2005-09-01

• Fields of study

  Medicine

• Identifiers
  PMID 16101159
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells

  2004cited by this paper
• Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study

  2003cited by this paper
• Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer.

  2003cited by this paper
• Ecologic studies of solar UV-B radiation and cancer mortality rates.

  2003cited by this paper
• Prostatic 25‐hydroxyvitamin D‐1α‐hydroxylase and its implication in prostate cancer

  2003cited by this paper
• 25-Hydroxyvitamin D-1α-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer

  2002cited by this paper
• An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet‐B radiation

  2002cited by this paper
• Dihydrotestosterone (DHT) modulates the ability of NSAIDs to induce apoptosis of prostate cancer cells

  2002cited by this paper
• Superior effectiveness of ibuprofen compared with other NSAIDs for reducing the survival of human prostate cancer cells

  2002cited by this paper
• Growth inhibitory effects of 1alpha, 25-dihydroxyvitamin D(3) are mediated by increased levels of p21 in the prostatic carcinoma cell line ALVA-31.

  2001cited by this paper
• Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition.

  2001cited by this paper
• Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland)

  2000cited by this paper
• Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study.

  2000cited by this paper
• A Phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy.

  1999cited by this paper
• Antiproliferative Effect of 1α,25-Dihydroxyvitamin D3 in Human Prostate Cancer Cell Line LNCaP Involves Reduction of Cyclin-Dependent Kinase 2 Activity and Persistent G1 Accumulation.

  1998cited by this paper
• Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation.

  1998cited by this paper
• Induction of the differentiation of HL-60 promyelocytic leukemia cells by nonsteroidal anti-inflammatory agents in combination with low levels of vitamin D3.

  1998cited by this paper
• Clinical Pharmacokinetics of Ibuprofen

  1998cited by this paper
• The novel analog 1,24(S)-dihydroxyvitamin D2 is as equipotent as 1,25-dihydroxyvitamin D3 in growth regulation of cancer cell lines.

  1998cited by this paper
• 1α,25-Dihydroxyvitamin D3 Actions in LNCaP Human Prostate Cancer Cells Are Androgen-Dependent.

  1997cited by this paper
• 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent.

  1997cited by this paper
• Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention.

  1996cited by this paper
• Control of LNCaP proliferation and differentiation: Actions and interactions of androgens, Iα,25‐dihydroxycholecalciferol, all‐trans retinoic acid, 9‐cis retinoic acid, and phenylacetate

  1996cited by this paper
• Vitamin D and prostate cancer: a prediagnostic study with stored sera.

  1993cited by this paper
• Effects of skin thickness, age, body fat, and sunlight on serum 25-hydroxyvitamin D.

  1993cited by this paper
• Newly identified actions of the vitamin D endocrine system.

  1992cited by this paper
• Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis).

  1990cited by this paper
• The role of the vitamin D endocrine system in health and disease.

  1989cited by this paper
• Vitamin D-deficiency in the elderly: treatment with ergocalciferol and hydroxylated analogues of vitamin D3.

  1988cited by this paper
• Aging Decreases the Capacity of Human Skin to Produce Vitamin D3

  1986cited by this paper
• Aging decreases the capacity of human skin to produce vitamin D3.

  1985cited by this paper

• The Potential Preventive and Therapeutic Roles of NSAIDs in Prostate Cancer

  2023cites this paper
• Safety and efficacy of high dose pulse calcitriol and docetaxel for androgen-independent prostate cancer

  2021cites this paper
• Graphene‐Based Materials for Implants

  2019cites this paper
• Long-term vitamin D treatment decreases human uterine leiomyoma size in a xenograft animal model.

  2019cites this paper
• Inhibition of tumor cell proliferation in human uterine leiomyomas by vitamin D via Wnt/β-catenin pathway.

  2019cites this paper
• Application of Carbon-Based Nanomaterials as Drug and Gene Delivery Carrier

  2017cites this paper
• Mechanistic Insights of Vitamin D Anticancer Effects.

  2016cites this paper
• Calcitriol in Combination Therapy for Prostate Cancer: Pharmacokinetic and Pharmacodynamic Interactions

  2016cites this paper
• A pH-sensitive nanocarrier for co-delivery of doxorubicin and camptothecin to enhance chemotherapeutic efficacy and overcome multidrug resistance in vitro

  2015cites this paper
• Recent Advances in Upconversion Nanoparticles‐Based Multifunctional Nanocomposites for Combined Cancer Therapy

  2015cites this paper
• Biomedical Applications of Graphene

  2012cites this paper
• R-flurbiprofen, a novel nonsteroidal anti-inflammatory drug, decreases cell proliferation and induces apoptosis in pituitary adenoma cells in vitro

  2012cites this paper
• Vitamin D effects on differentiation and cell cycle

  2011cites this paper
• TRPV6 Determines the Effect of Vitamin D3 on Prostate Cancer Cell Growth

  2011cites this paper
• Vitamin D and Prostate Cancer

  2011cites this paper
• Calcitriol and Vitamin D Analogs

  2010cites this paper
• Functional graphene oxide as a nanocarrier for controlled loading and targeted delivery of mixed anticancer drugs.

  2010cites this paper
• Vitamin D in combination cancer treatment

  2010cites this paper
• Effekte der systemischen Cholecystokiningabe bei C57BL/6-Mäusen und Einfluss einer chronischen Vitamin D- und /oder Paroxetinbehandlung auf das Verhalten und die HPA-Ahcse bei C57BL/6- und DBA/2-Mäusen

  2009cites this paper
• Zyflamend in men with high-grade prostatic intraepithelial neoplasia: results of a phase I clinical trial.

  2009cites this paper
• TITLE: Induction of the p75NTR by Aryl Propionic Acids in Prostate Cancer Cells

  2009cites this paper
• Potential use of cholecalciferol polyethylene glycol succinate as a novel pharmaceutical additive.

  2008cites this paper
• CONTRACT NUMBER Induction of the p 75 NTR by Aryl Propionic Acids in Prostate Cancer Cells

  2007cites this paper
• The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells.

  2007cites this paper
• TITLE: Induction of the p75NTR by Aryl Propionic Acids in Prostate Cancer Cells

  2007cites this paper
• Efficient dual treatment of the hormone-refractory prostate cancer cell line DU145 with cetuximab and 1,25-dihydroxyvitamin D3.

  2007cites this paper
• Epigenetics—DNA-Based Mirror of our Environment?

  2007cites this paper
• Afectará el cambio climático a la mortalidad por cáncer de próstata

  2007cites this paper
• Vitamin D Analogs and Their Role in Prostate Cancer

  2006cites this paper
• Prognostic significance of vitamin D receptor and retinoid X receptor expression in renal cell carcinoma.

  2006cites this paper